Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ia, Multicenter, Double-Blind, Placebo-controlled Study to Evaluate the Safety of CYT-108 for the Therapy of Mild to Moderate Primary Osteoarthritis of the Knee

Trial Profile

A Phase Ia, Multicenter, Double-Blind, Placebo-controlled Study to Evaluate the Safety of CYT-108 for the Therapy of Mild to Moderate Primary Osteoarthritis of the Knee

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CYT 108 (Primary)
  • Indications Osteoarthritis
  • Focus Adverse reactions; First in man; Pharmacodynamics
  • Sponsors Cytonics Corporation

Most Recent Events

  • 01 Apr 2025 According to Cytonics Corporation media release, Phase 1 is now complete, and the team is focused on cleaning and locking the database.
  • 01 Apr 2025 Status changed from active, no longer recruiting to completed. The last patient has completed their last visit.
  • 21 Jan 2025 According to Cytonics Corporation media release,first nine patients in this trial successfully completed the study.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top